Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Markets Daily

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, fifteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $1,052.90.

Several brokerages have weighed in on REGN. Leerink Partners restated a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st.

View Our Latest Analysis on Regeneron Pharmaceuticals

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the last quarter. Catalyst Financial Partners LLC raised its position in Regeneron Pharmaceuticals by 3.8% in the 2nd quarter. Catalyst Financial Partners LLC now owns 326 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 12 shares during the period. Finally, Trust Co. of Vermont lifted its stake in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $715.13 on Thursday. The firm has a market capitalization of $78.59 billion, a P/E ratio of 17.70, a P/E/G ratio of 2.19 and a beta of 0.08. Regeneron Pharmaceuticals has a 52 week low of $693.00 and a 52 week high of $1,211.20. The stock has a 50 day moving average price of $821.00 and a two-hundred day moving average price of $994.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

(Get Free Report

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More